TC
SGMO

TFS Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

TFS Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-20,220
Closed -$94K – 877
2016
Q3 		$94K Sell
20,220
-132
-0.6% -$671 0.02% 654
2016
Q2 		$118K Sell
20,352
-70,619
-78% -$450K 0.02% 838
2016
Q1 		$550K Buy
+90,971
New +$546K 0.08% 415
2015
Q4 		– Sell
-46,971
Closed -$265K – 885
2015
Q3 		$265K Buy
46,971
+4,660
+11% +$38.4K 0.03% 682
2015
Q2 		$469K Buy
+42,311
New +$546K 0.05% 553
2015
Q1 		– Sell
-10,561
Closed -$161K – 1114
2014
Q4 		$161K Sell
10,561
-8,864
-46% -$108K 0.02% 851
2014
Q3 		$209K Sell
19,425
-141,497
-88% -$1.85M 0.02% 859
2014
Q2 		$2.46M Buy
+160,922
New +$2.32M 0.19% 141
2014
Q1 		– Sell
-18,714
Closed -$260K – 1553
2013
Q4 		$260K Buy
+18,714
New +$215K 0.01% 1161

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FC
FIC Capital New York $262M AUM 34.37% 1-Year Est. Return

TFS Capital's SGMO Position: Q4 2016 in Review

TFS Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2016, closing a stake of 20,220 shares — an estimated $94K sold.

TFS Capital first reported a position in SGMO in Q4 2013 and held it in 9 quarters. The position peaked at $2.46M in Q2 2014. 126 funds tracked by Wall St. Rank hold SGMO as of Q4 2016.

  • TFS Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2016 after selling out during the quarter.
  • TFS Capital sold 20,220 SANGAMO THERAPEUTICS INC shares in Q4 2016, an estimated $94K.
  • TFS Capital first reported a position in SANGAMO THERAPEUTICS INC in Q4 2013 and held it in 9 quarters.
  • TFS Capital's SANGAMO THERAPEUTICS INC position peaked at $2.46M in Q2 2014.
  • 126 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2016.

Based on TFS Capital's 13F filing for Q4 2016, filed 20 Jan 2017.